B7-H3: a robust target for immunotherapy in prostate cancer

IF 14.3 1区医学 Q1 ONCOLOGY

Trends in cancer Pub Date : 2024-06-04 DOI:10.1016/j.trecan.2024.05.003

Rafael Pulido, José I. López, Caroline E. Nunes-Xavier

引用次数: 0

Abstract

B7-H3, an immune checkpoint glycoprotein, facilitates immune evasion and the promotion of tumors and is highly expressed on the surface of prostate cancer (PCa) cells, which makes it a feasible and robust candidate for immunotherapies against advanced prostate cancer. Here, we summarize and discuss recent findings on the suitability of targeting B7-H3 in PCa treatment.

查看原文本刊更多论文

B7-H3：前列腺癌免疫疗法的强大靶点

B7-H3是一种免疫检查点糖蛋白，可促进免疫逃避和肿瘤的生长，并在前列腺癌（PCa）细胞表面高度表达，这使其成为针对晚期前列腺癌的免疫疗法的一个可行且稳健的候选靶点。在此，我们总结并讨论了最近关于靶向 B7-H3 治疗 PCa 的研究结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Trends in cancer Medicine-Oncology

CiteScore

28.50

自引率

0.50%

发文量

138

期刊介绍： Trends in Cancer, a part of the Trends review journals, delivers concise and engaging expert commentary on key research topics and cutting-edge advances in cancer discovery and medicine. Trends in Cancer serves as a unique platform for multidisciplinary information, fostering discussion and education for scientists, clinicians, policy makers, and patients & advocates.Covering various aspects, it presents opportunities, challenges, and impacts of basic, translational, and clinical findings, industry R&D, technology, innovation, ethics, and cancer policy and funding in an authoritative yet reader-friendly format.